Drug Trial Radar · NCT05114096
Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,254
Planned (sponsor's estimate)
Start
Jul 20, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- McMaster UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hamilton Health Sciences Corporation; Sunnybrook Research Institute; Women's and Children's Hospital, Australia; Canadian Institutes of Health Research (CIHR); Medical Research Future Fund; University of Adelaide
- First posted
- Nov 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome. The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity. The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.
Conditions
- Preterm Birth
- Premature Birth
- Complication of Prematurity
- Obstetric Labor, Premature
- Pregnancy Complications
Interventions
Celestone + placeboDrug
After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.
Celestone + CelestoneDrug
After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Perinatal Mortality or Substantial Neonatal MorbidityTime frame: approximately 1 month
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
University of Calgary, Cumming School of Medicine
Calgary, Alberta, Canada · Recruiting
Alberta Health Services; University of Alberta
Edmonton, Alberta, Canada · Recruiting
Royal Columbian Hospital
New Westminster, British Columbia, Canada · Not yet recruiting
Fraser Health, University of British Columbia; Jim Pattison Outpatient Care and Surgery Centre
Surrey, British Columbia, Canada · Not yet recruiting
University of British Columbia; BC Women's Hospital
Vancouver, British Columbia, Canada · Not yet recruiting
Victoria General Hospital
Victoria, British Columbia, Canada · Not yet recruiting
University of Manitoba, Health Sciences Centre
Winnipeg, Manitoba, Canada · Not yet recruiting
University of Manitoba; St. Boniface General Hospital
Winnipeg, Manitoba, Canada · Not yet recruiting
Dr. Everett Chalmers Regional Hospital
Fredericton, New Brunswick, Canada · Recruiting
The Moncton Hospital, Horizon Health Network
Moncton, New Brunswick, Canada · Recruiting
Memorial University, Eastern Health
St. John's, Newfoundland and Labrador, Canada · Not yet recruiting
Dalhousie University; Izaak Walton Killam Health
Halifax, Nova Scotia, Canada · Recruiting
McMaster University
Hamilton, Ontario, Canada · Recruiting
Queen's University, Kingston General Hospital Health Sciences Centre
Kingston, Ontario, Canada · Recruiting
Western University; London Health Sciences Centre, Victoria Hospital
London, Ontario, Canada · Recruiting
University of Ottawa; The Ottawa Hospital
Ottawa, Ontario, Canada · Recruiting
Mount Sinai Hospital
Toronto, Ontario, Canada · Recruiting
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada · Recruiting
Hopital Maisonneuve Rosemont, CIUSSS de l'est de l'Ile de Montréal
Montreal, Quebec, Canada · Recruiting
McGill University, McGill University Health Center, Royal Victoria Hospital
Montreal, Quebec, Canada · Recruiting
Sir Mortimer B. Davis Jewish General Hospital; McGill University
Montreal, Quebec, Canada · Not yet recruiting
The Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal
Montreal, Quebec, Canada · Recruiting
Université Laval, Centre de recherche du CHU de Québec
Québec, Quebec, Canada · Recruiting
(CIUSSS de l'Estrie-CHUS); Université de Sherbrooke
Sherbrooke, Quebec, Canada · Recruiting
University of Saskatchewan, Regina General Hospital
Saskatoon, Saskatchewan, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.